Platinum-based Agents are Not Superior to Standard Chemotherapy for Patients with Breast Cancer Who Carry BRCA Mutations
Teresa Herbert (BIDMC Communications) 617-667-7305, firstname.lastname@example.org
MARCH 04, 2020
Designed to settle a question raised by previous studies, INFORM is the largest prospective randomized clinical trial to compare the efficacy of a platinum agent to a standard treatment regimen. The INFORM trial was led by Nadine Tung, MD, Director of the Cancer Risk and Prevention Program and head of Breast Medical Oncology at Beth Israel Deaconess Medical Center (BIDMC).
“Previous studies reported that the platinum-based therapy cisplatin was effective in BRCA carriers with breast cancer,” said Tung. “Those findings left clinicians uncertain whether to use cisplatin – an unconventional drug for treating early stage breast cancer – or whether to use the same chemotherapy regimen used for other women with breast cancer. Prior to INFORM, no randomized prospective data existed comparing platinum to standard chemotherapy in this population of patients. Our study found that platinum-based therapy was actually no more effective than the standard first-line treatment.”
Linked to five percent of breast cancer cases among the general population, BRCA mutations are responsible for a larger proportion of breast cancer in younger women, Jewish women, and those with a family history of breast cancer. BRCA mutations are identified in 10 to 20 percent of women with the type of breast cancer known as triple negative breast cancer.
As part of the INFORM trial, Tung and colleagues at 13 medical centers recruited 117 patients newly-diagnosed with but not yet treated for breast cancer who were also known to carry one or both of the two known BRCA mutations. Fifty-seven of these patients were treated with the standard first-line chemotherapy, doxorubicin combined with cyclophosphamide (AC), while 60 patients were treated with cisplatin. All participants underwent mastectomy or lumpectomy, followed lymph node biopsy or dissection after completing their respective courses of treatment.
The results of the INFORM trial demonstrate that, while cisplatin is an active agent for treating breast cancer in BRCA carriers, it is not more effective than the standard chemotherapy regimen AC. Tung and colleagues reported that among participants treated with cisplatin, the overall pathologic complete response rate – the disappearance of all cancer at surgery – was 18 percent compared with 26 percent with the AC regimen.
“We demonstrated that both regimens can be effective and treatment choice may need to incorporate an individual’s other health concerns and anticipated side effects with each regimen,” Tung said.
Further analysis of the data revealed that, among women with triple-negative breast cancer, pathologic complete response rates were 22 percent and 28 percent, respectively. Among patients with another subtype of breast cancer known as hormone receptor–positive breast cancer, response rates were six percent and 21 percent, respectively.
The number of patients with complete or near complete disappearance of cancer, termed Residual Cancer Burden 0 or 1, was also numerically but not statistically higher with AC than cisplatin, for all breast cancer subtypes.
“Given the previously reported impressive activity of platinum agents in BRCA-associated breast cancer, these results were surprising,” Tung noted. “The INFORM trial underscores the importance of confirming results from single arm trials with randomized trials.”
In addition to Tung, co-authors included Michelle R. Hacker (statistician) from BIDMC, Stuart J. Schnitt (the study pathologist), and senior author Judy E. Garber of Dana-Farber Cancer Institute. Co-authors include Andrew J. Goss, and Colby Jenkins of BIDMC; Banu Arun of the University of Texas MD Anderson Cancer Center; Erin Hofstatter of Yale Cancer Center; Deborah L. Toppmeyer of Rutgers Cancer Institute; Steven J. Isakoff of Massachusetts General Hospital; Virginia Borges of University of Colorado Cancer Center; Robert D. Legare of Women and Infants Hospital; Claudine Isaacs of Lombardi Comprehensive Cancer Center; Antonia C. Wolff of Johns Hopkins Kimmel Cancer Center; Paul Kelly Marcom of Duke Medical Center; Erica L. Mayer, Paulina B. Lange, Ian E. Krop and Eric P. Winer of Dana-Farber Cancer Institute.
This work was supported by funding from the Breast Cancer Research Foundation; Susan G. Komen; and Myriad Genetics, Inc.
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.
BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Rehabilitation Center and is a research partner of Dana-Farber/Harvard Cancer Center and the Jackson Laboratory. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org.
BIDMC is part of Beth Israel Lahey Health, a new health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,000 physicians and 35,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.